Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
Bretylium tosylate is an injectable antiarrhythmic agent approved in 1986 for the treatment of life-threatening ventricular arrhythmias. Administered intravenously, it works through adrenergic inhibition and direct myocardial effects to stabilize cardiac rhythm. It is primarily used in acute care and emergency settings for patients with hemodynamically significant arrhythmias.
As LOE approaches, commercial teams are likely focused on maximizing remaining market share against strong competitor pressure (30/100 competitive intensity), with potential workforce realignment anticipated post-exclusivity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bretylium tosylate offers limited career growth opportunities given its LOE approaching status and minimal linked job postings, suggesting a small, stable team focused on managed decline. Professionals joining this product should expect emphasis on efficiency, cost control, and market defense rather than expansion or innovation.
Worked on BRETYLIUM TOSYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.